REGN vs XPER · P/E 14, rev $14.34B vs rev $493.7M
Regeneron Pharmaceuticals Inc (REGN) versus Xperi Corp (XPER) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Xperi Corp (XPER) is a software - application company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported XPER revenue for 2024-12-31 was $493.7M. Net income was -$869.0K. Revenue was down 5.3% from 2023-12-31 to 2024-12-31. XPER currently screens at market cap $367.8M.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. XPER currently screens at market cap $367.8M.
Not investment advice. Open the REGN and XPER stock pages for the full models.
Not investment advice.